Loading stock data…
QNCX
$0.97-0.03 (-3.00%)
After Hours$1.01+0.04 (+4.09%)· Last close Jun 9
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Quince Therapeutics, Inc. in the Healthcare sector is trading at $0.97 with a market capitalization of $19M. The stock is currently near its 52-week low of $0.79, remaining 92.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.97
Potential Downside
0%
Whystock Fair Value$0.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$18.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-210.80%
Volume
Today's trading volume
804,714
Recent News
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. Quince Therapeutics, Inc. (NASDAQ:QNCX) is among the most popular penny stocks. TheFly reported that QNCX presented Phase 2a clinical results for LAM-001 on May 18, at the American Thoracic Society conference in Orlando, evaluating an inhaled rapamycin formulation […]
BC-Most Active Stocks
Elong Power Holding Ltd. 329,453,698 0.1034
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls
Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital
D. Boral Capital analyst Jason Kolbert raised the firm’s price target on Quince Therapeutics (QNCX) to $5 from $4 and keeps a Buy rating on the shares after the company said the last patient has completed their last visit in the pivotal Phase 3 NEAT clinical trial evaluating encapsulated dexamethasone sodium phosphate in patients with Ataxia-Telangiectasia. The firm cites the rolling of its valuation metrics out a year for the target bump. Claim 50% Off TipRanks Premium and Invest with Confidenc